연구업적

연도	2024년	2023년	2022년	2021년	2020년
SCI 논문 발표편수	책임	179편	173편	163편	184편	135편
공동	147편	120편	115편	136편	168편
합계	326편	293편	278편	320편	303편

3467. Plain language summary of the FOENIX-CCA2 study: futibatinib for people with advanced bile duct cancer

Lipika Goyal 1, Funda Meric-Bernstam 2, Antoine Hollebecque 3, Juan W Valle 4 5, Chigusa Morizane 6, Thomas B Karasic 7, Thomas A Abrams 8, Junji Furuse 9, Robin Katie Kelley 10, Philippe A Cassier 11, Heinz-Josef Klümpen 12, Heung-Moon Chang 13, Li-Tzong Chen 14, Josep Tabernero 15, Do-Youn Oh 16, Amit Mahipal 17, Markus Moehler 18, Yoshito Komatsu 19, Daniel H Ahn 20, Robert S Epstein 21, Abdel-Baset Halim 22, Volker Wacheck 22, Yaohua He 22, Mei Liu 22, Karim A Benhadji 22, John A Bridgewater

Future Oncol. 2024;20(36):2811-2822. Link

3466. An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202

A Vogel 1, V Sahai 2, A Hollebecque 3, G M Vaccaro 4, D Melisi 5, R M Al Rajabi 6, A S Paulson 7, M J Borad 8, D Gallinson 9, A G Murphy 10, D-Y Oh 11, E Dotan 12, D V Catenacci 13, E Van Cutsem 14, C F Lihou 15, H Zhen 15, M L Veronese 16, G K Abou-Alfa 17

ESMO Open. 2024 Jun;9(6):103488. Link

3465. Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study

Bob T Li 1, Funda Meric-Bernstam 2, Aditya Bardia 3, Yoichi Naito 4, Salvatore Siena 5, Philippe Aftimos 6, Ian Anderson 7, Giuseppe Curigliano 8, Maria de Miguel 9, Maitri Kalra 10, Do-Youn Oh 11, Joon Oh Park 12, Sophie Postel-Vinay 13, Sun Young Rha 14, Taroh Satoh 15, Iben Spanggaard 16, Flavia Michelini 17, Ann Smith 18, Karime Kalil Machado 19, Cristina Saura 20; DESTINY-PanTumor01 study group

Lancet Oncol. 2024 Jun;25(6):707-719. Link

3464. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial

Howard A Burris 3rd 1, Takuji Okusaka 2, Arndt Vogel 3, Myung Ah Lee 4, Hidenori Takahashi 5, Valeriy Breder 6, Jean-Frédéric Blanc 7, Junhe Li 8, Melinda Bachini 9, Magdalena Żotkiewicz 10, Jayne Abraham 11, Nikunj Patel 12, Julie Wang 12, Muzammil Ali 12, Nana Rokutanda 12, Gordon Cohen 12, Do-Youn Oh 13

Lancet Oncol. 2024 May;25(5):626-635. Link

3463. Clinical practice guidelines for esophagogastric junction cancer: Upper GI Oncology Summit 2023

Yuko Kitagawa # 1, Satoru Matsuda # 2, Takuji Gotoda 3, Ken Kato 4 5, Bas Wijnhoven 6, Florian Lordick 7, Pradeep Bhandari 8, Hirofumi Kawakubo 2, Yasuhiro Kodera 9, Masanori Terashima 10, Kei Muro 11, Hiroya Takeuchi 12, Paul F Mansfield 13, Yukinori Kurokawa 14, Jimmy So 15, Stefan Paul Mönig 16, Kohei Shitara 17, Sun Young Rha 18, Yelena Janjigian 19, Daisuke Takahari 20, Ian Chau 21, Prateek Sharma 22, Jiafu Ji 23, Giovanni de Manzoni 24, Magnus Nilsson 25, Paulo Kassab 26, Wayne L Hofstette

Gastric Cancer. 2024 May;27(3):401-425. Link

3462. Pharmacokinetics (PK) of Tiragolumab in First-in-Human Study in Patients with Mixed Solid Tumors (GO30103)

Elena Garralda 1, Do Youn Oh 2, Antoine Italiano 3, Philippe L Bedard 4, Jean-Pierre Delord 5, Emiliano Calvo 6, Patricia LoRusso 7, Zev Wainberg 8, Andres Cervantes 9 10, Alejo Rodriguez-Vida 11, Colby S Shemesh 12, Rucha Sane 12, Diana Mendus 13, Hao Ding 12, Robert Hendricks 14, Ray Meng 13, Byoung Chul Cho 15, Tae Won Kim 16, Benjamin Wu 1 2

J Clin Pharmacol. 2024 May;64(5):544-554. Link

3461. A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors

Benjamin Garmezy 1, Mitesh J Borad 2, Rastilav Bahleda 3, Cesar A Perez 4, Li-Tzong Chen 5, Shumei Kato 6, Do-Youn Oh 7, Paul Severson 8, Betty Y Tam 9, Cheng S Quah 8, James J Harding 10

Cancer Res Commun. 2024 Apr 30;4(4):1165-1173. Link

3460. Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1-4 Inhibitor: Pooled Safety Analysis of 469 Patients

Funda Meric-Bernstam 1, Antoine Hollebecque 2, Junji Furuse 3, Do-Youn Oh 4 5, John A Bridgewater 6, Masashi Shimura 7, Bailey Anderson 7, Nanae Hangai 7, Volker Wacheck 7, Lipika Goyal 8 9

Clin Cancer Res. 2024 Apr 15;30(8):1466-1477 Link

3459. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study

Kohei Shitara 1, Sun Young Rha 2, Lucjan S Wyrwicz 3, Takashi Oshima 4, Nina Karaseva 5, Mikhail Osipov 6, Hisateru Yasui 7, Hiroshi Yabusaki 8, Sergey Afanasyev 9, Young-Kyu Park 10, Salah-Eddin Al-Batran 11, Takaki Yoshikawa 12, Patricio Yanez 13, Maria Dib Bartolomeo 14, Sara Lonardi 15, Josep Tabernero 16, Eric Van Cutsem 17, Yelena Y Janjigian 18, Do-Youn Oh 19, Jianming Xu 20, Xiao Fang 21, Chie-Schin Shih 21, Pooja Bhagia 21, Yung-Jue Bang 22; KEYNOTE-585 investigators

Lancet Oncol. 2024 Feb;25(2):212-224. Link

3458. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

Funda Meric-Bernstam 1, Vicky Makker 2 3, Ana Oaknin 4, Do-Youn Oh 5, Susana Banerjee 6, Antonio González-Martín 7, Kyung Hae Jung 8, Iwona Ługowska 9, Luis Manso 10, Aránzazu Manzano 11, Bohuslav Melichar 12, Salvatore Siena 13, Daniil Stroyakovskiy 14, Anitra Fielding 15, Yan Ma 16, Soham Puvvada 15, Norah Shire 15, Jung-Yun Lee 17

J Clin Oncol. 2024 Jan 1;42(1):47-58. Link

최근 5년 연구업적 현황